Investor Alert

New York Markets Close in:

Sept. 25, 2021, 4:25 a.m. EDT

Xpeng Inc XPEV Proactive Strategies

Sep 25, 2021 (Stock Traders Daily via COMTEX) -- Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in Xpeng Inc (NYS:XPEV) with integrated risk controls.

The trading plans were valid at the time this was published, but the support and resistance levels for XPEV change as time passes, and this should be updated in real time. Access those real time updates for this and 1000 other stocks here. Unlimited Real Time Reports

Protection from Market Crashes: Subscribers also get our Tail Risk hedge, Evitar Corte

Use the basic rules of Technical Analysis. Here are some examples: if XPEV is testing support the signal is to buy and target resistance. On the other hand, if resistance is tested, that is a sign to short, and target support. No matter which side the trade is, long or short, the trigger point is both a place to enter and as a risk control.

This data can be used to define Day Trading, Swing Trading, and Long Term Investing plans for XPEV too. All of these are offered here: Access our Real Time Trading Plans

  • Buy XPEV over 30.03 target 40.79 stop loss @ 29.94

  • Short XPEV under 40.79, target 30.03, stop loss @ 40.91

  • Buy XPEV over 36.70, target 40.79, Stop Loss @ 36.59

  • Short XPEV near 36.70, target 35.11, Stop Loss @ 36.81.

  • Buy XPEV over 35.80, target 36.82, Stop Loss @ 35.72

  • Short XPEV near 35.80, target 35.11, Stop Loss @ 35.88.

XPEV Technical Summary | Raw Data for the Trading Plans

Bias Weak Weak Strong
P1 0 0 30.03
P2 35.80 35.11 40.79
P3 36.82 36.70 54.17


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Link to MarketWatch's Slice.